Use the Search facility to find fascinating facts about this unique molecule, HOCl


The use of HOCl in the realm of medical treatment was first mentioned in 1915.


Benefits were soon recognised in July 1916


Medical use against Covid-19

The Colima study (Mexico)

A clinical trial using volunteer patients, all diagnosed as positive for Covid 19. Both control (n=45), and the experimental group (n=39)  were all given appropriate conventional medical therapies and support. The experimental group were, in addition, prescribed HOCl treatment firstly in nebulised form (inhalation of fine droplets) and in rising levels, by intravenous delivery.

31% of the patients without HOCl care deteriorated and were hospitalised, but only 11% of the experimental group required hospital care at a later date.

13% of the control group died, but no deaths were seen in the experimental group treated with escalating doses of HOCl.

The experimental group patients also reported a faster rate of recovery.

Safety and efficacy of a COVID‑19 treatment with nebulized and/or intravenous neutral electrolyzed saline combined with usual medical care vs. usual medical care alone: A randomized, open‑label, controlled trial

Medicins Sans Frontiers support inclusion of HOCl on the Essential Medicine list of the World Health Organisation

"MSF urges the 23rd Expert Committee on the Selection and Use of Essential Medicines to include hypochlorous acid in the WHO Model List of Essential Medicines."

Interestingly however, MSF do not appear to recognise NaDCC (sodium dichloroisocyanurate) as being a source of HOCl.

“Hypochlorous acid is a well-studied, non-toxic, non-corrosive, easy to use compound, and a more effective and a safer alternative to other chlorine generating disinfectant agents, such as sodium dichloroisocyanurate (NaDDC)”